Chemicals & Small Molecules

Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.

Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.

Avizakimab (BOS161721), a humanized IgG1 monoclonal antibody, specifically targets interleukin-21 [1].

Axatilimab (SNDX-6352) is a human IgG4 antibody targeting the colony-stimulating factor 1 receptor (CSF-1R), which can be used for the study of immune system disorders and respiratory diseases.

Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity for use in investigational stage malignant solid tumors.

Bepranemab (UCB 0107) is a humanized anti-tau monoclonal antibody of the IgG class for the study of Alzheimer's disease (AD) and tau protein disorders.

Zelminemab (AMG-301) is a humanized monoclonal antibody targeting the pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1) for use in neurological disorders.

Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.

Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.